Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

252 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
T cell-engaging BiTE antibodies specific for EGFR potently eliminate KRAS- and BRAF-mutated colorectal cancer cells.
Lutterbuese R, Raum T, Kischel R, Hoffmann P, Mangold S, Rattel B, Friedrich M, Thomas O, Lorenczewski G, Rau D, Schaller E, Herrmann I, Wolf A, Urbig T, Baeuerle PA, Kufer P. Lutterbuese R, et al. Among authors: baeuerle pa. Proc Natl Acad Sci U S A. 2010 Jul 13;107(28):12605-10. doi: 10.1073/pnas.1000976107. Epub 2010 Jun 28. Proc Natl Acad Sci U S A. 2010. PMID: 20616015 Free PMC article.
MT110: a novel bispecific single-chain antibody construct with high efficacy in eradicating established tumors.
Brischwein K, Schlereth B, Guller B, Steiger C, Wolf A, Lutterbuese R, Offner S, Locher M, Urbig T, Raum T, Kleindienst P, Wimberger P, Kimmig R, Fichtner I, Kufer P, Hofmeister R, da Silva AJ, Baeuerle PA. Brischwein K, et al. Among authors: baeuerle pa. Mol Immunol. 2006 Mar;43(8):1129-43. doi: 10.1016/j.molimm.2005.07.034. Epub 2005 Sep 1. Mol Immunol. 2006. PMID: 16139892
Therapeutic window of an EpCAM/CD3-specific BiTE antibody in mice is determined by a subpopulation of EpCAM-expressing lymphocytes that is absent in humans.
Amann M, Friedrich M, Lutterbuese P, Vieser E, Lorenczewski G, Petersen L, Brischwein K, Kufer P, Kischel R, Baeuerle PA, Schlereth B. Amann M, et al. Among authors: baeuerle pa. Cancer Immunol Immunother. 2009 Jan;58(1):95-109. doi: 10.1007/s00262-008-0529-y. Epub 2008 Jul 2. Cancer Immunol Immunother. 2009. PMID: 18594818 Free PMC article.
Mode of cytotoxic action of T cell-engaging BiTE antibody MT110.
Haas C, Krinner E, Brischwein K, Hoffmann P, Lutterbüse R, Schlereth B, Kufer P, Baeuerle PA. Haas C, et al. Among authors: baeuerle pa. Immunobiology. 2009;214(6):441-53. doi: 10.1016/j.imbio.2008.11.014. Epub 2009 Jan 20. Immunobiology. 2009. PMID: 19157637
Potent control of tumor growth by CEA/CD3-bispecific single-chain antibody constructs that are not competitively inhibited by soluble CEA.
Lutterbuese R, Raum T, Kischel R, Lutterbuese P, Schlereth B, Schaller E, Mangold S, Rau D, Meier P, Kiener PA, Mulgrew K, Oberst MD, Hammond SA, Baeuerle PA, Kufer P. Lutterbuese R, et al. Among authors: baeuerle pa. J Immunother. 2009 May;32(4):341-52. doi: 10.1097/CJI.0b013e31819b7c70. J Immunother. 2009. PMID: 19342971
Antitumor activity of an EpCAM/CD3-bispecific BiTE antibody during long-term treatment of mice in the absence of T-cell anergy and sustained cytokine release.
Amann M, D'Argouges S, Lorenczewski G, Brischwein K, Kischel R, Lutterbuese R, Mangold S, Rau D, Volkland J, Pflanz S, Raum T, Münz M, Kufer P, Schlereth B, Baeuerle PA, Friedrich M. Amann M, et al. Among authors: baeuerle pa. J Immunother. 2009 Jun;32(5):452-64. doi: 10.1097/CJI.0b013e3181a1c097. J Immunother. 2009. PMID: 19609237
252 results